Evidence map›Paper›PMID 26631169›Full record

ArticlePflugers Archiv : European journal of physiology2016

Nicorandil stimulates a Na⁺/Ca²⁺ exchanger by activating guanylate cyclase in guinea pig cardiac myocytes.

Jiazhang Wei, Yasuhide Watanabe, Kazuhiko Takeuchi, Kanna Yamashita, Miyuki Tashiro, Satomi Kita, Takahiro Iwamoto, Hiroshi Watanabe, Junko Kimura

Abstract read
PubMed Publisher
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Cardiac NaThe journal of physiological sciences : JPS · 2019
    Review
  5. Pinacidil, a KATP channel opener, stimulates cardiac NaNaunyn-Schmiedeberg's archives of pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jiazhang WeiDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.
Yasuhide WatanabeDivision of Pharmacological Science, Department of Health Science, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan. w-yasu@hama-med.ac.jp.
Kazuhiko TakeuchiDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.
Kanna YamashitaDivision of Pharmacological Science, Department of Health Science, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.
Miyuki TashiroDivision of Pharmacological Science, Department of Health Science, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.
Satomi KitaDepartment of Pharmacology, Faculty of Medicine, Fukuoka University, Fukuoka, 814-0180, Japan.
Takahiro IwamotoDepartment of Pharmacology, Faculty of Medicine, Fukuoka University, Fukuoka, 814-0180, Japan.
Hiroshi WatanabeDepartment of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.
Junko KimuraDepartment of Pharmacology, Fukushima Medical University, Fukushima, 960-1295, Japan.
Hamamatsu University School of Medicine · JPFukuoka University · JPFukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nicorandil, a hybrid of an ATP-sensitive K(+) (KATP) channel opener and a nitrate generator, is used clinically for the treatment of angina pectoris. This agent has been reported to exert antiarrhythmic actions by abolishing both triggered activity and spontaneous automaticity in an in vitro study. It is well known that delayed afterdepolarizations (DADs) are caused by the Na(+)/Ca(2+) exchange current (I NCX). In this study, we investigated the effect of nicorandil on the cardiac Na(+)/Ca(2+) exchanger (NCX1). We used the whole-cell patch clamp technique and the Fura-2/AM (Ca(2+) indicator) method to investigate the effect of nicorandil on I NCX in isolated guinea pig ventricular myocytes and CCL39 fibroblast cells transfected with dog heart NCX1. Nicorandil enhanced I NCX in a concentration-dependent manner. The EC50 (half-maximum concentration for enhancement of the drug) values were 15.0 and 8.7 μM for the outward and inward components of I NCX, respectively. 8-Bromoguanosine 3',5'-cyclic monophosphate (8-Br-cGMP), a membrane-permeable analog of guanosine 3',5'-cyclic monophosphate (cGMP), enhanced I NCX. 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a guanylate cyclase inhibitor (10 μM), completely abolished the nicorandil-induced I NCX increase. Nicorandil increased I NCX in CCL39 cells expressing wild-type NCX1 but did not affect mutant NCX1 without a long intracellular loop between transmembrane segments (TMSs) 5 and 6. Nicorandil at 100 μM abolished DADs induced by electrical stimulation with ouabain. Nicorandil enhanced the function of NCX1 via guanylate cyclase and thus may accelerate Ca(2+) exit via NCX1. This may partially contribute to the cardioprotection by nicorandil in addition to shortening action potential duration (APD) by activating KATP channels.

Indexed as

Action PotentialsAnimalsAnti-Arrhythmia AgentsCalciumCell LineCells, CulturedCricetinaeCricetulusDogsGuanylate CyclaseGuinea PigsHeart VentriclesMaleMyocytes, CardiacNicorandilSodium-Calcium ExchangerAnti-Arrhythmia AgentsCalciumGuanylate CyclaseNicorandilSodium-Calcium ExchangerCardiac myocytesCyclic GMPKATP channel openerNa+/Ca2+ exchange current (I NCX)Nicorandil

Identifiers

PMID26631169
OpenAlexW2257803629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.